ALK and non-small cell lung carcinoma: To this regard, an interesting meta-analysis by Kuan Li Wu et al. [42] considering Asian patients from six different studies (CROWN, ALTA1L, ALEX, J-ALEX, ALESIA and eXalt3), recently confirmed that, although all ALK-i included in the analysis proved superior to crizotinib in treatment naïve NSCLC patients, ensartinib may be the best choice in first line in this population for PFS.